Jacobs Levy Equity Management Inc. Lowers Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jacobs Levy Equity Management Inc. cut its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 34.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 281,478 shares of the company's stock after selling 148,326 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.21% of Organogenesis worth $805,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in Organogenesis by 15.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company's stock valued at $87,000 after purchasing an additional 4,130 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Organogenesis by 11.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company's stock valued at $145,000 after purchasing an additional 5,359 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company's stock valued at $68,000 after purchasing an additional 7,678 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company's stock valued at $63,000 after purchasing an additional 9,048 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Organogenesis by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company's stock valued at $755,000 after purchasing an additional 9,054 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Organogenesis news, CEO Gary S. Gillheeney sold 41,052 shares of the company's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $3.52, for a total value of $144,503.04. Following the transaction, the chief executive officer now directly owns 3,359,726 shares in the company, valued at $11,826,235.52. This represents a 1.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 36.90% of the company's stock.

Organogenesis Trading Up 5.1 %

NASDAQ:ORGO traded up $0.18 during mid-day trading on Tuesday, hitting $3.68. 593,155 shares of the stock traded hands, compared to its average volume of 846,899. The stock has a market capitalization of $487.89 million, a price-to-earnings ratio of -61.33 and a beta of 1.73. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70. The firm's 50 day moving average is $3.39 and its two-hundred day moving average is $2.98. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the prior year, the firm posted $0.02 EPS. On average, equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.